Frontier Capital Management Co. LLC Acquires 91,227 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Frontier Capital Management Co. LLC increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 50.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 272,088 shares of the medical device company's stock after buying an additional 91,227 shares during the quarter. Frontier Capital Management Co. LLC owned 0.41% of Tandem Diabetes Care worth $9,801,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in TNDM. JPMorgan Chase & Co. grew its stake in shares of Tandem Diabetes Care by 134.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after buying an additional 113,355 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter. US Bancorp DE raised its position in shares of Tandem Diabetes Care by 15.2% during the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after buying an additional 5,108 shares during the last quarter. KBC Group NV raised its holdings in Tandem Diabetes Care by 41.5% in the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock valued at $6,933,000 after acquiring an additional 56,461 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in Tandem Diabetes Care by 22.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after purchasing an additional 1,184 shares during the period.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction dated Friday, March 7th. The stock was purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TNDM shares. Piper Sandler lowered their target price on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Wells Fargo & Company lowered their price objective on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Mizuho began coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price target on the stock. Robert W. Baird lowered their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. Finally, Stifel Nicolaus cut their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $39.81.

Tandem Diabetes Care Stock Performance

TNDM traded down $0.32 during trading on Tuesday, hitting $23.13. The stock had a trading volume of 1,464,168 shares, compared to its average volume of 1,503,041. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The company has a 50 day moving average price of $18.75 and a 200-day moving average price of $28.08. Tandem Diabetes Care, Inc. has a one year low of $15.75 and a one year high of $53.69. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -11.98 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same quarter last year, the business earned ($0.65) EPS. Tandem Diabetes Care's revenue was up 22.3% on a year-over-year basis. As a group, research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.